{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:51:21Z","timestamp":1780599081317,"version":"3.54.1"},"reference-count":16,"publisher":"Medknow","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0019-5154.190107","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T09:42:13Z","timestamp":1473932533000},"page":"550","source":"Crossref","is-referenced-by-count":26,"title":["Belimumab in systemic lupus erythematosus"],"prefix":"10.4103","volume":"61","author":[{"given":"Ankita","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"key":"key-10.4103\/0019-5154.190107-1","first-page":"317","volume-title":"Belimumab:First targeted biological treatment for systemic lupus erythematosus","author":"Dubey","year":"2011","journal-title":"J Pharmacol Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/0976-500X","issn-type":"print"},{"key":"key-10.4103\/0019-5154.190107-2","first-page":"e000011","volume-title":"Belimumab in systemic lupus erythematosus","author":"Vilas-Boas","year":"2015","journal-title":"RMD Open"},{"key":"key-10.4103\/0019-5154.190107-3","first-page":"704207","volume-title":"Health technology assessment of belimumab: A new monoclonal antibody for the treatment of systemic lupus erythematosus","author":"Specchia","year":"2014","journal-title":"Biomed Res Int"},{"key":"key-10.4103\/0019-5154.190107-4","first-page":"69","volume-title":"The discovery and development of belimumab: The anti-BLyS-lupus connection","author":"Stohl","year":"2012","journal-title":"Nat Biotechnol"},{"key":"key-10.4103\/0019-5154.190107-5","first-page":"115","volume-title":"Belimumab in systemic lupus erythematosus: A perspective review","author":"Hui-Yuen","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key-10.4103\/0019-5154.190107-6","first-page":"71","volume-title":"Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis","author":"Frieri","year":"2015","journal-title":"J Pharmacol Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/0976-500X","issn-type":"print"},{"key":"key-10.4103\/0019-5154.190107-7","unstructured":"Label Approved on 03\/10\/2011 (PDF) for BENLYSTA, BLA No. 125370. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125370s0000lbl.pdf. [Last accessed on 2016 Apr 07]."},{"key":"key-10.4103\/0019-5154.190107-8","first-page":"1","volume-title":"The BLyS family: Toward a molecular understanding of B cell homeostasis","author":"Treml","year":"2009","journal-title":"Cell Biochem Biophys"},{"key":"key-10.4103\/0019-5154.190107-9","first-page":"3918","volume-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.190107-10","first-page":"333","volume-title":"Current and emerging treatment options for ANCA-associated vasculitis: Potential role of belimumab and other BAFF\/APRIL targeting agents","author":"Lenert","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/0019-5154.190107-11","first-page":"100","volume-title":"Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases","author":"Raychaudhuri","year":"2009","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0019-5154.190107-12","first-page":"300","volume-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","author":"Ginzler","year":"2014","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.190107-13","first-page":"144","volume-title":"Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus","author":"Wallace","year":"2013","journal-title":"Lupus"},{"key":"key-10.4103\/0019-5154.190107-14","first-page":"3364","volume-title":"Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus","author":"Merrill","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.190107-15","first-page":"711","volume-title":"A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab","author":"Fredericks","year":"2014","journal-title":"Lupus"},{"key":"key-10.4103\/0019-5154.190107-16","first-page":"721","volume-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","author":"Navarra","year":"2011","journal-title":"Lancet"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T09:47:25Z","timestamp":1473932845000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.e-ijd.org\/text.asp?2016\/61\/5\/550\/190107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["190107"],"URL":"https:\/\/doi.org\/10.4103\/0019-5154.190107","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}